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1. Introduction 
Cancer immunotherapy is the use of the immune system to reject cancers. The main premise 
is to harness the patient's immune system to attack the malignant tumor cells. This area of 
research has made tremendous progresses, and the United States Food and Drug 
Administration recently approved a vaccine for prostate cancers as the first approval for 
vaccines against non-viral cancers (Kantoff et al., 2010). However, when it comes to central 
nervous system (CNS) tumors, while early phase immunotherapy trials showed 
encouraging outcomes, the immunological microenvironment of the CNS and tumors 
arising in the CNS is still believed to be suboptimal for sufficient antitumor immune 
responses to mediate clinically-meaningful changes in situ (Okada, H. et al., 2009; Walker, P. 
R. et al., 2003). In this chapter, we first discuss recent advances in the CNS and CNS tumor 
immunology. We address factors that may promote immune escape of gliomas. We also 
review advances in passive and active immunotherapy strategies for glioma, with an 
emphasis on lessons learned from recent early phase clinical trials. We also discuss novel 
immunotherapy strategies that have been recently tested in non-CNS tumors with great 
potential for application to CNS tumors. We will finally discuss how each of these 
promising strategies can be combined to achieve clinical benefit for patients with CNS 
tumors. 
2. Immunology of gliomas 
2.1 Immunology of CNS 
For many decades, the brain has been considered an immune-privileged site due to the 
presence of a blood brain barrier (BBB) and the lack of lymphatics (Ransohoff et al., 2003). 
More recent studies have revealed crucial components involved in the process of leukocyte 
migration towards the CNS and the mechanisms of neuroinflammatory reactions in the CNS 
(Ransohoff et al., 2003). This section will focus on three key issues of CNS immunology: 1) 
factors limiting inflammation in the CNS, 2) antigen-specific immune response in the CNS, 
and 3) immune cell trafficking towards the CNS. In-depth understanding of these aspects 
will allow us to gain a framework to improve current treatment strategies harnessing the 
immune system to treat brain tumors. 
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2.1.1 Factors limiting inflammation in the CNS 
Cells composing the CNS are extremely sensitive to the toxic effects of exogenous 
substances. Therefore, the CNS and the neurovasculature system therein have evolved 
specialized mechanisms to control both molecular and cellular migration into and out of the 
CNS parenchyma and cerebral spinal fluid (CSF). Capillary endothelial cells in the CNS are 
termed the BBB due to their ability to restrict passive diffusion and maintain low pinocytotic 
activity, and neuroimmunologists synonymously use the term BBB to describe both the 
capillary and post capillary vessels, the latter of which is the site of T-cell migration into the 
brain (Ransohoff et al., 2003). This "barrier" results from the selectivity of the tight junctions 
(TJs) between endothelial cells in the CNS vessels that restrict the passage of large 
hydrophilic molecules (i.e. peptides and proteins) and cells (Abbott et al., 2006). 
Many extracellular proteins have been studied as TJ proteins: primarily the occludin, 
claudin, and junctional adhesion molecule (JAM) families. Experimental characterization of 
each has shown that mice carrying a null mutation in the occludin gene develop normal TJs 
whereas claudins have been shown to be independently sufficient for TJ formation 
(Engelhardt, 2008), suggesting the importance of claudins in TJ formation and regulation. 
Additionally, intravenous injection of monoclonal antibodies blocking JAM into mice 
inhibits leukocyte accumulation in CSF and brain parenchyma presumably through 
blocking leukocyte transmigration at the BBB (Engelhardt, 2008). 
2.1.2 Induction of Immune responses to CNS antigens 
The classic paradigm of specific immune activation is achieved through antigen uptake by 
antigen-presenting cells (APCs), which migrate to the lymph nodes via draining lymphatics 
where APCs subsequently activate T-cells. In the systemic immune system, dendritic cells 
(DCs) are considered to be the most potent APCs. In the CNS, a variety of cell populations 
have been postulated as primary CNS APCs, including vascular endothelial cells, smooth 
muscle cells, astrocytes, perivascular macrophages, choroid plexus epithelial cells, neurons, 
and DCs (Dunn et al., 2007). Among them, microglia has been proposed to be the primary 
resident APCs in the CNS (Aloisi, 2001). 
Presentation of CNS antigens can occur through multiple mechanisms (Walker, P. R. et al., 
2003): 1) APC uptake antigen within the CNS and migrate to lymph nodes to present 
antigens; 2) antigen drains to lymph nodes where APCs take them up to present, and 3) cells 
that express the antigen directly drain to lymph nodes and present their own antigen (direct 
presentation as opposed to cross presentation by DCs). Indeed, DCs injected in brain tumors 
have been shown to migrate to the cervical lymph nodes (CLNs) (Dunn et al., 2007). In 
addition, autoantigens from brain lesions have been shown to drain to CLNs in both 
primate models of experimental allergic encephalomyelitis and human multiple sclerosis (de 
Vos et al., 2002). Concurrently, it has been shown that tumor-specific T-cells can be primed 
in CLNs in murine glioma models (Fujita et al., 2009; Kuwashima et al., 2005; Okada, N. et 
al., 2005). 
2.1.3 Migration of immune cells towards the CNS 
Lymphocytes traffic to the CNS through the following 4 steps: 1) tethering/rolling, 2) 
activation, 3) adhesion, and 4) transmigration (Engelhardt, 2008). Interactions between 
carbohydrates on leukocytes and adhesion molecules (usually selectins) on endothelial cells 
slow down the leukocytes. Chemokines (e.g. CXCL10) are released from a site of 
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inflammation and form a concentration gradient in endothelial membrane and attract 
responsible leukocytes such as activated T-cells (Fujita et al., 2009; Nishimura et al., 2006). At 
a reduced velocity, the leukocytes sense chemokines on the endothelial cells, become 
activated through G-protein signaling, and up-regulate integrins such as very late antigen 4 
(VLA-4) (Sasaki et al., 2007; Sasaki et al., 2008a; Sasaki et al., 2008b; Sasaki et al., 2009). 
Lymphocyte function-associated molecules (LFAs) on lymphocytes allow for a stable 
interaction to their ligands vascular cell adhesion proteins (VCAMs) and inter-cellular 
adhesion molecules (ICAMs) on endothelial cells. Finally, with this tight interaction in place, 
the cells transmigrate into the parenchyma. 
2.2 Immunosuppression by gliomas 
Previously characterized immunological impairments in glioma patients have included low 
peripheral lymphocyte counts, reduced delayed-type hypersensitivity reactions to recall 
antigens, and impaired proliferating responses by peripheral blood mononuclear cells 
(PBMCs). Gliomas are known to achieve these by producing imunosuppressive molecules 
and inducing immunosuppressive leukocytes. 
2.2.1 Immunosuppressive factors 
Transforming growth factor β (TGF-β) 
TGF-ǃ is the most potent immunosuppressive cytokine; its biological effects are multiple and 
complex (Gorelik et al., 2002). They include the inhibition of 1) APC maturation 2) antigen 
presentation of APCs, 3) T-cell activation, and 4) their differentiation towards effector cells. 
Recent studies have shown that TGF-ǃ is up-regulated in glioma cell clones that are resistant to 
the cytotoxic effects of allogeneic cytotoxic T-cells (CTLs), suggesting the significance of TGF-ǃ 
in glioma immune escape mechanisms (Gomez et al., 2007; Ueda et al., 2009). 
Interleukin 10 (IL-10) 
IL-10 is also known to be a strong immunosuppressive cytokine (Moore et al., 2001). Like 
TGF-ǃ, this cytokine has pleiotropic effects in immunoregulation and inflammation. It 
down-regulates the expression of Th1 cytokines, MHC class II antigens, and costimulatory 
molecules on APCs. The expression levels of IL-10 in glioma tissue correlate with glioma 
grade as well as a degree of brain invasiveness (Huettner et al., 1997; Nitta et al., 1994). 
Prostaglandin E2 (PGE2) 
PGE2 is a product of arachadonic acid metabolism. It is produced at sites of inflammation or 
tissue damage where it exerts many effects including the enhancement of vascular 
permeability. As PGE2 has profound modulatory effects on T-cell activation and gliomas 
synthesize PGE2, it is associated with the suppressed T-cell function observed in patients 
with gliomas (Castelli et al., 1989). In addition, we recently demonstrated that PGE2 
production from murine gliomas induces accumulation of tumor-associated myeloid cells 
that promote growth of gliomas (Fujita et al., 2011). 
CCL2; macrophage chemoattractive protein 1 (MCP-1) 
CCL2, also known as MCP-1, is a chemokine secreted by a variety of glioma cell lines and 
expressed in glioblastoma multiforme (GBM) (Desbaillets et al., 1994; Takeshima et al., 
1994). In addition to its angiogenetic effects (Salcedo et al., 2000), it is associated with 
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recruitment of immunosuppressive leukocytes, such as tumor-associated macrophages and 
regulatory T cells (Fujita et al., 2010; Fujita et al., 2011; Huang et al., 2007; Jordan et al., 2008). 
Fas receptor/ligand 
The Fas receptor is a death receptor on the surface of cells that leads to apoptosis. Malignant 
gliomas express Fas ligand, which induces apoptotic cell death of adjacent immune cells 
infiltrating into tumors sites (Walker, P. R. et al., 1997). In addition, Fas receptor expressed 
on glioma cells induces proinflammatory and angiogenic mediators, which in turn protect 
and support tumors growth (Shinohara et al., 2000). 
B7-homologue 1 (B7-H1); programmed death ligand-1 (PD-L1) 
The B7 family consists of co-stimulatory molecules that positively and negatively regulate 
immune responses. Among them, B7-H1, also known as PD-L1, exerts immunosuppressive 
functions when interacting with its receptor PD-1 (Chen, 2004). Glioma cells express B7-H1, 
which subsequently inhibits T-cell functions by decreasing cytokine production levels (IFN-
γ, IL-2, and IL-10) and expression levels of the T-cell activation marker CD69 (Wintterle et 
al., 2003). Glioma cells often exhibit mutations in a tumor-suppressor gene phosphatase and 
tensin homolog (PTEN), and loss of functions in PTEN also leads to up-regulation of B7-H1  
(Parsa et al., 2007). 
2.2.2 Immunosuppressive leukocytes 
A large number of observations suggest that certain types of immune cells in the tumor 
micrienvironment (TME) are not innocent bystanders at brain tumor sites, but they actively 
promote tumor development and progression. Inflammatory cells, primarily 
macrophage/microglia and regulatory T-cells, may affect these processes via their ability to 
express a large variety of factors, including immunoregulatory cytokines. These cytokines 
may be secreted not only by inflammatory cells, but also by the tumor cells and stroma cells, 
together establishing a network of factors that significantly affects brain tumor. 
Macrophages/microglia 
In the CNS, macrophage/microglial cells constitute the first line of cellular defense against a 
variety of stressors, participating in the regulation of innate and adaptive immune responses 
(Graeber et al., 2002). Resident microglias are CD11b+/CD45dim whereas macrophages are 
CD11b+/CD45high. Intratumoral macrophage/microglia density is higher than in normal brain 
and abundance of microglia correlates with the grade of malignancy (Badie et al., 2000). 
In contrast, the defense functions of macrophage/microglia against glioma are 
compromised in the TME. Although these cells express Toll-like receptors (TLRs), critical 
components for APCs to mediate innate immune responses and activate adaptive immune 
responses, those in the TME are unable to activate T-cells properly (Hussain et al., 2006). 
Consistently, macrophages/microglia release many factors, including extracellular matrix 
proteases (MMPs) and cytokines, which may directly or indirectly influence tumor 
migration/invasiveness and proliferation (Watters et al., 2005). In addition, glioma cell 
migration is stimulated by the presence of macrophage/microglia (Bettinger et al., 2002). 
Taken together, macrophages/microglias in gliomas promote the invasive phenotype of 
these tumors.  
Regulatory T-cells (Treg)  
The suppressive activity of Tregs has been implicated as an important factor limiting 
immune-mediated destruction of tumor cells. The presence of CD4+FoxP3+ Tregs correlates 
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with impairment of T-cell proliferation in peripheral blood specimens in GBM patients 
(Fecci et al., 2006). Moreover, tumor infiltration by Tregs correlates with tumor grade and 
prognosis (Heimberger et al., 2008). 
CD4+FoxP3+ Tregs in gliomas have been shown to express CD25, CTLA-4, GITR, and 
CXCR4 at high levels (Grauer et al., 2007). Intratumoral accumulation and activation of 
CD4+FoxP3+ Treg act as a dominant immune escape mechanism of gliomas and underline 
the importance of controlling tumor-infiltrating Treg in glioma immunotherapy. 
3. Immunotherapy for gliomas 
In this section, we will first discuss molecular targets for gliomas. Then, we will discuss two 
modalities: adoptive T-cell therapy (passive immunotherapy) and glioma vaccine (active 
immunotherapy). 
3.1 Target molecules for gliomas 
It is essential to know about potent target molecules for glioma immunotherapy. The 
following section will discuss selected human glioma-associated antigen (GAA)-derived 
epitopes that appear to be promising based on relatively restricted expression (compared 
with the normal brain) as well as well-characterized immunogenicity. 
IL-13Rα2 
IL-13Rǂ2 is a membrane glycoprotein that is overexpressed by >80% of malignant gliomas 
but is not expressed in normal brain tissues or other normal organs except for testes 
(Debinski et al., 1999). Therefore, IL-13Rα2 has attracted significant attention as a target for 
glioma therapy (Kahlon et al., 2004). We recently found that an analogue peptide of natural 
IL-13Rα2345-353, in which the first and ninth amino-acid residues tryptophan and isoleucine 
have been replaced by valine and alanine, respectively, can elicit a greater CTL response 
against HLA-A2+ IL-13Rα2+ glioma cells compared with the natural peptide (IL-13Rα2345-
353:1A9V) (Eguchi et al., 2006). 
EphA2 
EphA2 is a tyrosine kinase receptor that plays a role in carcinogenesis (Dodelet et al., 2000). 
We have reported that EphA2883-891 is expressed on gliomas and able to elicit an HLA-A2-
restricted CTL response against glioma cell lines (Hatano et al., 2005). Furthermore, EphA2 
mRNA overexpression was found to correlate inversely with survival in a panel of 21 GBMs 
(Liu et al., 2006). These findings support the idea that targeting of EphA2 by 
immunotherapy may provide a major impact in controlling tumor growth and prolonging 
patients’ survival.  
Survivin 
Survivin is an apoptosis inhibitor protein overexpressed in most human cancers including 
gliomas (Blanc-Brude et al., 2002; Uematsu et al., 2005). Therefore, induction of immune 
response against Survivin appears to be an attractive strategy. Of interest, high level 
expression of Survivin was correlated with poor prognosis in patients with grade II or III 
astrocytomas (Uematsu et al., 2005). 
Wilm’s tumor 1 (WT1) 
WT1 is a transcription factor oncogene that is overexpressed in various types of leukemia 
and solid tumor cells (Oka et al., 2002). Inhibition of WT1 in leukemic cell lines led to 
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decrease in proliferation and increase in apoptosis of tumor cells (Glienke et al., 2007). 
Human gliomas also express WT1 at high levels (Izumoto et al., 2008; Rushing et al., 2010; 
Schittenhelm et al., 2008). These finding imply that elimination of tumor cells that 
overexpress WT1 may allow efficient control against glioma growth. 
Sry-related high mobility group box (SOX) 
SOX is a family of transcriptional cofactors implicated in the control of diverse 
developmental processes and exhibit highly dynamic expression patterns during 
development of diverse tissues and cell types, especially during embryogenesis (Wegner, 
1999). Indeed, SOX2 (Gangemi et al., 2009), SOX5 (Ueda et al., 2007), SOX6 (Ueda et al., 
2004), and SOX11 (Schmitz et al., 2007) are highly expressed in glioma cell lines and a 
majority of glioma tissues. Their preferential expression in glioma and immunogenicity 
indicate that SOX proteins are attractive targets for immunotherapy. 
Type III variant of the EGFR mutation (EGFRvIII) 
EGFRvIII is present in 30-50% of patients with GBM. Despite the limited frequency in 
gliomas, EGFRvIII and IL-13Rα2 are expressed most restrictedly in primary glioma tissues 
compared with normal tissues (Saikali et al., 2007). Therefore, this antigen also appears to be 
an attractive target for glioma immunotherapy. 
Cytomegalovirus (CMV) 
Recent reports have demonstrated the presence of the cytomegalovirus (CMV) proteins as 
well as CMV mRNA in a majority of human GBMs (Barami, 2010; Cobbs et al., 2002; Lucas 
et al., 2010; Mitchell et al., 2008; Scheurer et al., 2008). Therefore, CMV in gliomas could 
serve as an immunotherapeutic target for glioma. In addition, the facilitation of an immune 
response against viral antigens contrasts with the difficulty of immunization against self 
antigens. It will be intriguing to introduce the CMV-derived epitope to multiepitope-based 
vaccine for glioma. 
3.2 Adoptive T-cell therapy (ACT) for gliomas 
ACT involves passive infusion or transfer of autologous CTLs specific for tumor antigens to the 
host. Although ACT are currently evaluated as experimental therapy for limited types of 
cancers (Gattinoni et al., 2006; Morgan et al., 2006), this strategy may hold promise as an 
attractive future immunotherapeutic intervention against gliomas. In particular, based on 
strong findings that CTLs have the capacity to migrate into brain parenchyma (Ransohoff et al., 
2003), the approach has been vastly improved by the use of recent advances in several areas of 
human T-cell biology including in vitro human T-cell culture and ex vivo genetic manipulation. 
This section will focus on recent technological advances in ACT as well as a current and future 
ACT for glioma with an emphasis on recent perspectives from human studies. 
3.2.1 Source of glioma-reactive CTLs 
Peripheral Bloods 
PBMCs from glioma patients can be expanded in vitro through multiple cycles of antigenic 
stimulation. Subsequently, cells with a monoclonal specificity to the particular GAA will be 
generated. Although few numbers of GAA-reactive CTLs might be obtained this method 
may be feasible as, this strategy has demonstrated favorable anti-tumor responses in cancer 
patients (Gattinoni et al., 2006). 
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Glioma tissues 
Another important source of the GAA-specific CTLs is a glioma tissue itself. A tumor 
nodule contains tumor-reactive CTLs that can be first polyclonally expanded ex vivo in the 
presence of IL-2 and later selected for antigen specificity (Rosenberg, 2008). These CTLs 
derived from tumor nodules have been used for ACT in melanoma patients (Dreno et al., 
2002; Dudley et al., 2005). 
3.2.2 Manipulation of glioma-reactive CTLs ex vivo 
Choice of T-cell subtypes 
In general, an effector T-cell subset (TE) is predominantly enriched during ex vivo expansion 
for ACT. TE are generally considered to be terminally differentiated CTLs that have the 
highest cytotoxic capacity but lack appreciable proliferating capacity (Wherry et al., 2003). 
These cells would not be able to establish a long-term persisting population of tumor-
specific CTLs. There is a significant association between clinically favorable responses and 
the persistence of ex vivo expanded melanoma-specific CTL clones after infusion (Robbins et 
al., 2004). Therefore, efforts have been made to generate long-term persisting CTLs. In 
contrast to the TE subset, memory cells have enhanced proliferative potential and survival, 
and the potential to provide more robust and enduring protectin aganist tumors (Perret et 
al., 2008). In particular, recent studies have highlighted the potential of central memory T-
cells (TCM) as a source of TE for ACT (Wang et al., 2011; Yang et al., 2011). Yang et al. have 
shown that a large parcentage of in vitro generated antitumor CTLs mimick a TCM-like 
phenotype and function (Yang et al., 2011). In addition, Wang et al. have demonstrated that 
TCM are less prone to apoptosis and able to establish a persistent reservoir of functional T-
cells in mice (Wang et al., 2011). Furthermore, recent studies with human T-cell subsets have 
revealed that naïve CD8+ cells were not only the most abundant subset but also the 
population most capable of in vitro expansion and T-cell receptor (TCR) transgene 
expression. Despite increased expansion, naïve-derived cells displayed minimal effector 
differentiation, a quality associated with greater efficacy after cell infusion (Hinrichs et al., 
2011).  
Cloning of high-avidity T-cell receptors (TCRs) 
Since the majority of GAAs are poorly immunogenic to raise CTLs that possess TCRs with 
low avidity, a number of modification have been made for ACT. One of attempts is to 
systematically search tumor-specific CD8+ T-cells for clone(s) with higher TCR avidity, clone 
TCRǂ and ǃ genes, and exogenously induce the high-avidity TCR exogenously in bulk CD8+ 
T-cells. Li et al. used phage display to search for a high-avidity TCR against an HLA-A0201-
restricted epitope in a NY-ESO-1 antigen (Li et al., 2005). Moreover, ACT using high-avidity 
TCR transgenic T-cells have been shown to sustain in blood circulation at high levels 
engineered cells were observed at 1 year after infusion in 2 of 15 patients who both 
demonstrated objective regression of metastatic melanoma lesions (Morgan et al., 2006). 
These data suggest the therapeutic potential of genetically engineered high-avidity TCR 
clones for glioma immunotherapy. 
Establishment of chimeric antigen receptors (CARs) 
An interesting alternative to expression of high-avidity TCRs on T-cells is to express a 
chimeric molecule that has antigen-binding domains of a monoclonal antibody fused with a 
signal transduction domain of CD3 (Gross et al., 1989), namely chimeric antigen receptors 
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(CAR). A significant advantage of CARs over TCRs is that the antigen recognition is not 
restricted by expression of certain MHC class I molecules. Recently, CARs have been used to 
treat a number of cancers (Cartellieri et al., 2010). CAR-based approaches are currently being 
developed for gliomas as well (Kahlon et al., 2004; Ohno et al., 2010).  
3.2.3 Current attempts of ACT for gliomas 
There have been a number of clinical trials for malignant gliomas using ACT (Table1) 
(Vauleon et al., 2010).  Among them, three Phase I trials (Holladay et al., 1996; Plautz et al., 
1998; Wood et al., 2000) and two pilot studies (Plautz et al., 2000; Sloan et al., 2000) used 
CTLs obtained from lymph nodes or PBMCs after intradermal vaccination. Holladay et al. 
first conducted an ACT-based Phase I clinical trial and reported disease-free survival  ≥  8 
months in 7 of 15 patients (Holladay et al., 1996). Later, Wood et al. demonstrated a 
correlation between clinical response and the predominance of CD8+ T-cells to CD4+ cells in 
the injected cells (Wood et al., 2000). In addition, DTH response to autologous tumors was 
shown to correlate with clinical response (Sloan et al., 2000; Wood et al., 2000). However, 
 CTLs used in these studies were not specific for GAAs. Therefore, it is necessary to generate 
a library of human CTL clones against GAAs using advanced techniques described above. 
With such refinement of ex vivo T-cell manipulation, ACT may become a mainstream 
therapeutic intervention for malignant gliomas. 
 
Study Type of 
trials 
Patients Immune 
responses 
Clinical 
responses 
Holladay et al., 
1996 
Phase I N = 15 
recurrent HGG 
12 GBM, 3 AA 
DTH (15/15) No PR or SD 
Median FPS: ≥8 mo 
Plautz et al., 
1998) 
Phase I N = 10 
recurrent HGG 
9 GBM, 1 AA 
 3 PR 
Median FPS: > 12 mo 
Plautz et al., 
2000 
Pilot 
study 
N =9 
recurrent HGG 
6 GBM, 3 Gr3 
DTH (9/9) 3 PR 
Wood et al., 
2000 
Phase I N =12 
newly diagnosed 
glioma 
6 GBM, 2 Gr2, 4 Gr3 
DTH (12/12) 4 PR, 2 SD 
Correlation between clinical 
response and CD4/CD8 
composition of infused cells 
Sloan et al., 
2000 
Pilot 
study 
N =19 
recurrent HGG 
16 GBM, 2 AA, 
1 gliosarcoma 
DTH (17/19) 1 CR, 7 PR, 9 SD 
Median OS : 12 mo 
Correlation between survival 
and DTH response 
*Abbreviations used in this table. AA: anaplastic astrocytoma; CR: complete response; DTH: delayed-
type hypersensitivity; GBM: gliobrastoma; Gr2: WHO grade II glioma; Gr3: WHO grade III glioma; 
HGG: high-grade glioma; mo: month(s); OS: overall survival; PFS: progression-free survival; PR: partial 
response; SD: stable disease. 
Table 1. ACT-based clinical trials for glioma 
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3.3 Glioma vaccines 
In addition to the ACT strategy described above, we will discuss glioma vaccine strategies 
in this section. They include 1) whole glioma cell vaccines, 2) peptide-based vaccines 
targeting glioma-associated antigens, and 3) DC vaccines. 
3.3.1 Whole glioma cell vaccines 
Initial vaccination strategies for gliomas consisted of subcutaneous inoculations of 
irradiated, autologous (Wikstrand et al., 1980) or allogeneic (Zhang et al., 2007) glioma cells. 
This type of vaccine has the advantage of providing a panel of multiple potential GAAs that 
are naturally expressed by glioma cells. Especially, autologous glioma cells should allow 
immunizations against the most relevant GAAs expressed in the patient’s tumor (i.e. 
tailored medicine). Potential downsides of this approach, however, include: 1) cumbersome 
procedures and quality control (QC)/quality assurance (QA) issues associated with large 
scale cultures of autologous glioma cells and 2) theoretical risks of autoimmune 
encephalomyelitis (Wikstrand et al., 1980). Nevertheless, this type of vaccine strategy has 
been carefully examined (Table 2). Schneider et al. (Schneider et al., 2001) and Steiner et 
al.(Steiner et al., 2004) reported pilot clinical trials using autologous glioma cells modified 
 
Study Type of
trials 
Patients Tumor cell 
modification 
Immune 
responses 
Clinical 
responses 
Schneider et 
al., 2001 
Pilot 
study 
N =11 
newly diagnosed 
GBM 
infected with 
NDV, 
inactivated with 
cisplatinum 
DTH (11/11) 
T cell infiltrate 
(4/4) 
No survival 
benefit 
Andrews et 
al., 2001 
Pilot 
study 
N =12 
8 GBM, 4 AA 
IGF-RA/AS ODN T cell infiltrate
(4/9) 
2 CR, 4 PR, 2 SD 
Steiner et al., 
2004 
Pilot 
study 
N =23 GBM infected with 
NDV 
DTH (15/15) 
ELISPOT (3/3)
T cell infiltrate 
(6/7) 
1 CR 
Median OS: 
100 wks 
Parney et al., 
2006 
Pilot 
study 
N =6 
3 recurrent GBM 
3 melanoma 
transduced with
B7-2 and GM-CSF
No CTL activity Longer PFS 
(3/6 GBM) 
Ishikawa et al., 
2007 
Pilot 
study 
N =12 
8 newly diagnosed 
GBM, 4 recurrent 
GBM 
formalin-fixed DTH (9/12) 1 CR, 1 PR, 
2 MR 
Median OS: 
10.7 mo 
Clavreul et al., 
2010 
Phase I N =5 
recurrent HGG 
4 GBM, 1 AOA 
irradiated DTH (2/5) 3 SD 
*Abbreviations used in this table. AOA: anaplastic oligoastrocytoma; CTL: cytotoxic T-cells; ELISPOT: 
enzyme-linked immunosorbent spot; IGF-RA/AS ODN: insulin-like growth factoro type I receptor 
antisence oligodeoxynucleotide; MR: minor response; NDV: Newcastle-Disease-Virus; wk: week(s). 
Table 2. Autologous whole glioma cell vaccine trials. 
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 with Newcastle-Disease-Virus (NDV), which is known to serve as an vaccine adjuvant and 
therefore to improve the efficacy of glioma vaccines. Recently, Ishikawa et al. reported a 
Phase I clinical trial using formalin-fixed glioma tissues as a source of antigens (Ishikawa et 
al., 2007). The advantage of this strategy is that formalin fixation preserves the specific 
antigenicity of glioma cells. These studies reported no major adverse events. 
3.3.2 Peptide-based vaccines targeting glioma-associated antigens 
In vaccines using synthetic peptides for shared GAA-epitopes, advantages and 
disadvantages are distinct from those in whole glioma cell approaches. While synthetic 
GAA peptide-based vaccines may not adequately target antigens in each patient’s tumor, 
these vaccines have less concern for autoimmunity and provide “off the shelf” feasibility. 
Indeed, a wide range of peptide-based vaccines have been clinically evaluated (Table 3). 
Yajima et al. reported a phase I study of peptide-based vaccinations in patients with 
recurrent malignant gliomas (Yajima et al., 2005). In this study, prior to the first vaccine, 
each patient’s PBMCs were evaluated in vitro for cellular and humoral responses against a 
panel of antigens, and peptides that induced positive response were used for vaccinations. 
The regimen was well tolerated and resulted in an 89-week median survival of treated 
patients. However, there is little evidence that the antigens used in this study are expressed 
in gliomas at high levels. More recently, as the extension of the approach, Terasaki et al. 
reported a Phase I trial using 14 HLA-A24-binding peptides (Terasaki et al., 2011). They 
evaluated immune responses with dose escalation of peptides and defined 3 mg/peptide as 
the Phase II-recommended dose. Izumoto et al. reported a Phase II clinical trial using a 
single WT1 peptide (Izumoto et al., 2008). In this study, they reported a median progression-
free survival (PFS) of 20 weeks and a possible association between the WT1 expression 
levels and clinical responses. When single or oligo antigens are selected and targeted by 
vaccines, it also seems necessary to harness the concepts of epitope spreading to address the 
problems of tumor immune escape, while avoiding the augmentation of deleterious CNS 
autoimmune responses (Vanderlugt et al., 2002). Sampson et al. recently reported a Phase II 
study targeting the EGFRvIII epitope in newly diagnosed GBM patients who received gross 
total resection (Sampson et al., 2010). They reported a median PFS of 14.2 months and a 
median overall survival (OS) of 26.0 months. In addition, they identified that the 
development of specific antibody or delayed-type hypersensitivity responses to EGFRvIII 
significantly correlated with the OS. 
 
Study Type of
trials
Patients Peptide(s) Immune
responses
Clinical 
responses 
Yajima et al., 
2005 
Phase I N = 25
17 GBM, 8 Gr3
multiple DTH (11/21)
CTL  activity 
(14/21)
5 PR, 8 SD 
Median OS: 89 wks 
Izumoto et al., 
2008 
Phase II N = 21
recurrent GBM
WT1 DTH (21/21) 2 PR, 10 SD 
Median PFS: 20 wks 
Sampson et al., 
2010 
Phase II N = 18
newly diagnosed 
GBM
EGFRvIII DTH (5/9)
CTL activity 
(10/12)
Median PFS: 
14.2 months 
Median OS: 26.0 mo 
Terasaki et al., 
2011 
Phase I N = 12,
recurrent GBM
multiple CTL activity 
(8/12) 
1 PR, 7 SD 
Median PFS: 2.3 mo 
Median OS: 18.9 mo 
Table 3. Peptide-based vaccine trials for glioma. 
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3.3.3 DC vaccines 
DCs are the most potent antigen-presenting cells, driving the activation of T-cells in 
response to invading microorganisms (Banchereau et al., 2000). The availability to culture 
DCs from human peripheral blood monocytes has generated significant interest in using 
DCs in novel cancer vaccination strategies (Banchereau et al., 2000). 
To induce tumor-specific immune reaction via DCs, antigen elusion from tumor cells has 
been performed (Table 4). Yu et al. reported a Phase I trial of vaccinations using DCs pulsed 
with peptides eluted from autologous glioma cells (Yu et al., 2001). Later, Liau et al. also 
reported a Phase I trial in patients with newly diagnosed GBM using DCs pulsed with acid-
eluted glioma peptides (Liau et al., 2005). In this study, the authors reported the median OS 
of 23.4 months and that the benefit of the vaccine treatment was more evident in the 
subgroup of patients with slowly-progressing tumors and in those with tumors expressing 
low levels of TGF-ǃ2. 
 
Study Type of 
trials 
Patients Immune 
responses 
Clinical 
responses 
Yu et al., 
2001 
Phase I N = 9 
newly diagnosed 
HGG 
7 GBM, 2 AA 
CTL activity (4/7)
T cell infiltrate (2/4)
Median OS: 455 d 
Wheeler et al., 
2004 
Phase I/II N = 25 
newly diagnosed 
GBM 
CTL activity (8/24) 3 PR 
Liau et al., 
2005 
Phase I N = 12 GBM 
5 recurrent 
7 newly diagnosed 
CTL activity (6/12)
T cell infiltrate (4/8)
1 PR 
Median OS: 23.4 mo 
Table 4. DC-based vaccine trials using acid-eluted peptides. 
However, pulsing DCs with eluted peptides requires a large culture of autologous glioma 
cells and time-consuming procedures, for which QC/QA is not always feasible. To 
overcome this issue, glioma cell lysate has been used to pulse DCs in a number of trials 
(Table 5). Yamanaka et al. reported a Phase I/II study using DC pulsed with glioma lysate. 
Patients received either DCs matured with OK-432 or DCs without OK-432-mediated 
maturation (Yamanaka et al., 2003; Yamanaka et al., 2005). GBM patients receiving mature 
DCs had longer survival than those receiving DCs without OK-432-mediated maturation. 
Furthermore, patients receiving both intratumoral and intradermal DC administrations 
demonstrated longer overall survival than those with intradermal administrations alone 
(Yamanaka et al., 2005). Wheeler et al. reported another Phase II clinical trial with lysate-
pulsed DCs (Wheeler et al., 2008). IFN-Ǆ production levels from post-vaccine PBMC 
correlated significantly with patients’ survival and time to progression. Prins et al. recently 
reported a Phase I clinical trial in glioma patients using lysate-pulsed DCs (Prins et al., 
2011). Interestingly, their gene expression profiling in the participants’ GBM tissues 
demonstrated that the mesenchymal gene expression profile may represent a population of 
patients with favorable responses to their vaccines. 
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Study Type of 
trials 
Patients Immune 
responses 
Clinical 
responses 
Yamanaka 
et al., 2003 
Phase I/II N = 10 
7 GBM, 
3 recurrent Gr3 
DTH (3/6) 
ELISPOT (2/5) 
T cell infiltrate (2/2)
2 MR, 4 SD 
Median OS: > 200 
wks 
Yu et al., 
2004 
Phase I N = 14 
1 GBM, 1 AA, 
9 recurrent GBM, 
3 recurrent AA 
CTL activity (4/9)
T cell infiltrate (3/6)
Median OS: 133 wks 
Rutkowski 
et al., 2004 
Phase I N = 12 
recurrent HGG 
11 GBM, 1 others 
DTH (7/8) 2 CR, 1 PR, 1 SD 
Median OS: 10.5 mo 
Yamanaka 
et al., 2005 
Phase I/II N = 24 
recurrent HGG 
18 GBM, 6 Gr3 
DTH (8/17) 
ELISPOT (7/16) 
1PR, 3MR, 10 SD 
Median OS: 480 d 
Longer survival 
if DC maturation or 
IC injection 
Okada, H. 
et al., 2007 
Phase I N = 5 
newly diagnosed 
GBM 
No response No response 
Wheeler et al., 
2008 
Phase II N = 34 GBM 
23 recurrent 
11 newly diagnosed
ELISPOT (17/34) 3 CR, 1 PR 
Median OS: 642 d 
Correlation between 
survival and IFN-γ 
production 
De 
Vleeschouwer 
et al., 2004 
Phase I/II N = 56 
recurrent GBM 
DTH (11/ 23) Median OS: 9.6 mo 
Walker, D. G. 
et al., 2008 
Phase I N = 13 
9 GBM, 4 AA 
T cell infiltrate (3/3) 2 CR, 3 PR 
Ardon et al., 
2010 
Phase I/II N = 8 
newly diagnosed 
GBM 
DTH (2/5) 
ELISPOT (5/8) 
Median OS: 24 mo 
Prins et al., 
2011 
Phase I N = 23 GBM 
8 recurrent 
15 newly diagnosed
increase in systemic
TNF-ǂ and IL-6 
Median OS: 31.4 mo 
Better imune response 
if mesenchymal gene 
expression presents 
Table 5. DC-based vaccine trials using autologous tumor cell lysates. 
While these studies demonstrate early success of DC-based vaccines in glioma patients, 
based on our preclinical data demonstrating that type-1 CTLs are capable of mediating 
effective anti-CNS tumor immunity (Fujita et al., 2008; Nishimura et al., 2006), we recently 
completed a Phase I/II study of vaccines evaluating safety and immunological activities of 
vaccines using α-type-1-polarized DCs (αDC1) that are able to produce high levels of IL-12 
and induce long-lived type-1 T-cell responses (Okada, H. et al., 2011). In this study, patients 
with recurrent malignant glioma received intra-lymphnodal injection of ǂDC1 loaded with 
synthetic peptides for GAA epitopes and administration of polyinosinic-polycytidylic acid 
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[poly(I:C)] stabilized by lysine and carboxymethylcellulose (poly-ICLC) in HLA-A2+ 
patients with recurrent malignant gliomas. GAAs for these peptides are EphA2, IL-13R-ǂ2, 
YKL-40, and gp100. The regimen was well-tolerated and induced positive immune 
responses against at least one of the vaccination-targeted GAAs in peripheral blood 
mononuclear cells in 58% of patients. Peripheral blood samples demonstrated significant 
up-regulation of type 1 cytokines and chemokines, including interferon-ǂ and CXCL10. For 
at least 12 months, nine patients achieved progression-free status. One patient with 
recurrent GBM demonstrated a sustained complete response. IL-12 production levels by 
ǂDC1 positively correlated with time to progression. These data support safety, 
immunogenicity, and preliminary clinical activity of poly-ICLC-boosted ǂDC1-based 
vaccines and warrant further development of this approach. Although these Phase I/II 
studies demonstrate preliminary clinical efficacy, the ultimate judgment for clinical activity 
has to be made by rigorous evaluation in randomized studies. 
 
Study Type of
trials 
Patients Antigen 
Source 
Immune 
responses 
Clinical 
responses 
Kikuchi et al., 
2001 
Phase I N =8 
5 GBM, 2 AA, 1 AO
Fused 
tumor cells
ELISPOT (6/6) 1 MR,  6 SD 
Caruso et al., 
2004 
Phase I N =7 
recurrent tumors 
2 GBM, 1 AA, 4 
others 
tumor RNA No PBMC respnse 1 PR, 4 SD 
Kikuchi et al., 
2004 
Phase I N =15 
recurrent HGG 
6 GBM, 7 AA, 2 OAA
Fused 
tumor cells
DTH (15/15) 
CTL activity (2/8)
4 PR, 2 SD, 
1 MR 
Sampson 
et al., 2009 
Phase I N =12 
newly diagnosed 
GBM 
EGFRvIII DTH (5/9) 
CTL activity 
(10/12) 
Median OS: 
22.8 mo 
Okada, H. 
et al., 2011 
Phase 
I/II 
N = 22 
13 GBM, 5 AA, 
3 AO, 1 AOA 
EphA2, 
IL-13R-ǂ2, 
YKL-40, 
gp100 
ELISPOT (10/22)
increase in 
systemic Th1 
cytokines 
Median PFS: 
4 mo (GBM) 
13 mo (AG) 
Correlation 
between 
survival and 
DC-derived  
IL-12 levels 
Table 6. Other DC-based vaccine trials for glioma. 
4. Conclusion 
We reviewed recent progress in the field of brain and brain tumor immunology. We also 
reported recent progress and current challenges in immunotherapeutic strategies for brain 
tumors. It is clear that the CNS and gliomas are equipped with numerous and layered 
immunosuppressive and immune escape mechanisms, perhaps including ones that we have 
not yet identified. These discoveries, however, allow us to develop strategies to overcome 
each of these mechanisms. 
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Remaining unique challenges against gliomas include relative difficulties in obtaining tumor 
tissues following immunotherapeutic treatments. Unlike other cancers, intracranial glioma 
tissues are not readily accessible following vaccine treatment. Designing neo-adjuvant 
settings with vaccines is not always feasible because recurrent malignant gliomas, for which 
surgical resection is clinically indicated, typically do not allow us to wait for weeks before 
surgery and often require treatment with high dose corticosteroids. 
As reviewed in this article, the concept of immunotherapy has a diverse scope of strategies 
and target molecules. Extensive review of each field in this article has led us to identify the 
challenge for each strategy. Such challenges, however, may be overcome by appropriate 
combinations with other strategies. For example, ACT strategies may need to be combined 
with appropriate adjuvants and/or vaccinations to promote long lasting memory responses 
and anti-tumor immunosurveillance. However, when each of these agents is owned by 
separate industries with intellectual properties, such creative combinatorial strategies may 
not be implemented as efficiently as we would wish. Although several early phase clinical 
trials demonstrated promising therapeutic outcomes to date, clinical trials of 
immunotherapy for gliomas have not yet demonstrated objective proof of clinical efficacy in 
randomized studies. The eventual success of immunotherapies for brain tumors will be 
dependent upon not only an in-depth understanding of immunology behind the brain and 
brain tumors, but also the implementation of molecularly targeted trials that address 
multiple layers of challenges in brain tumors. 
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